Health Care · Surgical & Medical Instruments & Apparatus · Nasdaq · CIK 1127537 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $1.61Day +28.80%Mkt cap $53M1Y −48.9%Off 52W high −52.5%Vol (1Y) 100.3%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,363 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest2.5% of sh out |
| Days to cover4.6d |
| 13F net flow (QoQ)+2.12% |
| Top-10 13F concentration68.8% |
| Next report (est.)2026-10-28 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$88.5M |
| Earnings (TTM)-$53.2M |
| ROE−77.2% |
| Net margin−59.7% |
| ROIC−120.7% |
| Debt / equity0.68× |
| Sales growth 3Y19.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−27.1% |
| 1Y−48.9% |
| 3Y−88.5% |
| 5Y−95.9% |
| Since incept. (ann.)−48.0% |
Total return through 2026-07-30 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)100.3% |
| Ann. volatility (3Y)82.2% |
| Sharpe (1Y)−0.14 |
| Sharpe (3Y)−0.47 |
| Max drawdown (1Y)−62.9% |
| Max drawdown (3Y)−92.0% |
| Beta (3Y vs SPY)0.81 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | 4.7M | $6M | 11.19% | −0.1% |
| MORGAN STANLEY | 4.0M | $5M | 9.46% | −4.0% |
| Soleus Capital Management, L.P. | 2.8M | $4M | 6.60% | +36.8% |
| BlackRock, Inc. | 2.7M | $3M | 6.30% | −1.6% |
| ExodusPoint Capital Management, LP | 1.9M | $3M | 4.60% | −0.4% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.6M | $2M | 3.87% | new |
| BANK OF AMERICA CORP /DE/ | 1.2M | $2M | 2.76% | +60.3% |
| DEUTSCHE BANK AG\ | 1.2M | $2M | 2.76% | +3.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-29 | −$0.33 | — | $20.6M | −8.7% |
| 2025-12-31 | 2026-03-04 | — | — | $22.6M | −4.9% |
| 2025-09-30 | 2025-11-12 | −$0.34 | — | $21.5M | +5.5% |
| 2025-06-30 | 2025-07-30 | −$0.38 | — | $23.9M | +14.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-28 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
US 63% · EMEA 30% · Asia Pacific 7% · Other International Geographical Areas 0%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
